All In Biotech

Drug Trial Radar · NCT04271488

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

An Open-label Parallel-Group Study to Evaluate Pharmacokinetics of E7090 and Its Metabolite in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Feb 27, 2020

Primary completion

Aug 31, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Eisai Co., Ltd.Eisai
Sponsor type
Industry
First posted
Feb 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 79 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate the effects of mild and moderate hepatic impairment on PK of tasurgratinib after a single dose administration.

Conditions

  • Hepatic Impairment

Interventions

  • TasurgratinibDrug

    Tasurgratinib oral tablet.

  • TasurgratinibDrug

    Tasurgratinib oral capsule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax: Maximum Observed Plasma Concentration of TasurgratinibTime frame: Day 1: 0-144 hours postdose
  2. AUC(0-t): Area Under the Plasma Concentration versus Time Curve from Time 0 to Time of Last Quantifiable Concentration of TasurgratinibTime frame: Day 1: 0-144 hours postdose
  3. AUC(0-inf): Area Under the Plasma Concentration versus Time Curve from Time 0 to Infinity of TasurgratinibTime frame: Day 1: 0-144 hours postdose

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Eisai Trial Site #7

    Kyoto, Japan · Recruiting

  • Eisai Trial Site #6

    Hakata, Fukuoka, Japan · Recruiting

  • Eisai Trial Site #4

    Kurume, Fukuoka, Japan · Terminated

  • Eisai Trial Site #2

    Yuhu, Oita Prefecture, Japan · Recruiting

  • Eisai Trial Site #3

    Bukyo-ku, Tokyo, Japan · Recruiting

  • Eisai Trial Site #1

    Mintato-ku, Tokyo, Japan · Recruiting

  • Eisai Trial Site #8

    Shinjuku-ku, Tokyo, Japan · Recruiting

  • Eisai Trial Site #5

    Kofu, Yamanashi, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.